Jia Zhou

12.7k total citations · 4 hit papers
278 papers, 9.3k citations indexed

About

Jia Zhou is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Jia Zhou has authored 278 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Molecular Biology, 49 papers in Oncology and 36 papers in Cellular and Molecular Neuroscience. Recurrent topics in Jia Zhou's work include Receptor Mechanisms and Signaling (34 papers), Protein Degradation and Inhibitors (29 papers) and Bioactive Natural Diterpenoids Research (18 papers). Jia Zhou is often cited by papers focused on Receptor Mechanisms and Signaling (34 papers), Protein Degradation and Inhibitors (29 papers) and Bioactive Natural Diterpenoids Research (18 papers). Jia Zhou collaborates with scholars based in United States, China and Spain. Jia Zhou's co-authors include Haiying Chen, Eric A. Wold, Na Ye, Haijun Chen, Qiang Shen, Zhiqing Liu, Pei‐Yong Shi, Jimin Xu, Ye Ding and Chunyong Ding and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Jia Zhou

265 papers receiving 9.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity

2020 734 citations Wenjing Yang, Tianming Yu et al. Nature Communications profile →
Therapeutic Potential of Spirooxindoles as Antiviral Agents

2016 412 citations Na Ye, Haiying Chen et al. profile →
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

2024 56 citations Wei Wang, Najah Albadari et al. Pharmacological Reviews profile →
FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production

2024 42 citations Jia Zhou, Chuang Peng et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jia Zhou	5.6k	1.2k	1.2k	924	701	278	9.3k
Wolfgang Sippl	6.4k 1.1×	1.7k 1.4×	1.6k 1.3×	404 0.4×	929 1.3×	303	10.3k
Gregory D. Cuny	6.9k 1.2×	1.3k 1.0×	1.9k 1.6×	680 0.7×	1.4k 2.0×	165	11.5k
Hongzhuan Chen	6.0k 1.1×	1.1k 0.9×	626 0.5×	741 0.8×	430 0.6×	347	12.3k
Kennan C. Marsh	4.0k 0.7×	1.1k 0.9×	1.6k 1.3×	774 0.8×	675 1.0×	178	9.7k
Lucia Altucci	9.9k 1.8×	2.1k 1.7×	1.1k 0.9×	486 0.5×	1.0k 1.5×	321	14.5k
Brian R. Smith	4.3k 0.8×	1.5k 1.2×	2.6k 2.2×	845 0.9×	646 0.9×	125	10.5k
Stefano Moro	7.4k 1.3×	1.2k 1.0×	3.6k 3.0×	957 1.0×	411 0.6×	354	12.7k
Jonathan B. Baell	5.1k 0.9×	665 0.5×	2.5k 2.0×	497 0.5×	638 0.9×	177	9.2k
Hengming Ke	5.7k 1.0×	746 0.6×	1.0k 0.8×	376 0.4×	1.1k 1.5×	107	8.0k
Shu Zhang	4.6k 0.8×	1.9k 1.5×	601 0.5×	492 0.5×	1.2k 1.7×	351	9.6k

Countries citing papers authored by Jia Zhou

Since Specialization

Citations

This map shows the geographic impact of Jia Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jia Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jia Zhou more than expected).

Fields of papers citing papers by Jia Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jia Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jia Zhou. The network helps show where Jia Zhou may publish in the future.

Co-authorship network of co-authors of Jia Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Jia Zhou. A scholar is included among the top collaborators of Jia Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jia Zhou. Jia Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Changying, Qingsong Cai, Yang Liu, et al.. (2025). YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma. Blood Advances. 9(19). 4963–4976.

Chen, Haiying, et al.. (2025). A New Era of Artificial Intelligence (AI): Transforming Drug Discovery and Development. Journal of Medicinal Chemistry. 68(22). 23643–23652. 1 indexed citations

Li, Jun, Hamid Soraya, Jimin Xu, et al.. (2025). Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge. Antiviral Research. 238. 106155–106155. 2 indexed citations

Tang, You, Bo Sun, Jia Zhou, et al.. (2025). Integration of Meta-Analysis and Network Pharmacology to Investigate the Pharmacological Mechanisms of Quercetin on Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark. 30(11). 46289–46289.

Wang, Pingyuan, et al.. (2024). Orphan GPR52 as an emerging neurotherapeutic target. Drug Discovery Today. 29(4). 103922–103922. 9 indexed citations

Wang, Wei, Najah Albadari, Wa Xian, et al.. (2024). MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacological Reviews. 76(3). 414–453. 56 indexed citations breakdown →

Bonam, Srinivasa Reddy, et al.. (2023). BRD4 as a potential target for human papillomaviruses associated cancer. Journal of Medical Virology. 95(12). e29294–e29294. 1 indexed citations

Ma, Zonghui, et al.. (2023). RIPTACs: A groundbreaking approach to drug discovery. Drug Discovery Today. 28(11). 103774–103774. 14 indexed citations

Zhou, Jia, et al.. (2023). Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022). European Journal of Medicinal Chemistry. 256. 115476–115476. 70 indexed citations

10.

Chen, Xiaoxiao, et al.. (2023). FeNi-modified carbon nanotube arrays on silicon carbide fibers for electromagnetic wave absorption. Ceramics International. 49(22). 36715–36723. 18 indexed citations

11.

Chen, Jianping, et al.. (2021). Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment. Current Topics in Medicinal Chemistry. 21(31). 2771–2777. 5 indexed citations

12.

Wang, Pingyuan, Dharini van der Hoeven, Na Ye, et al.. (2021). Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. European Journal of Medicinal Chemistry. 217. 113381–113381. 8 indexed citations

13.

Liu, Gang, Hye‐Jin Kim, Pingyuan Wang, et al.. (2021). Further lead optimization on Bax activators: Design, synthesis and pharmacological evaluation of 2-fluoro-fluorene derivatives for the treatment of breast cancer. European Journal of Medicinal Chemistry. 219. 113427–113427. 8 indexed citations

14.

Wang, Xinye, Ting Qiu, Yingying Wu, et al.. (2021). Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer. Cell Death and Differentiation. 28(10). 2931–2945. 42 indexed citations

15.

Zafar, Atif, Wei Wang, Gang Liu, et al.. (2020). Molecular targeting therapies for neuroblastoma: Progress and challenges. Medicinal Research Reviews. 41(2). 961–1021. 229 indexed citations

16.

Yang, Wenjing, Tianming Yu, Xiangsheng Huang, et al.. (2020). Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nature Communications. 11(1). 4457–4457. 734 indexed citations breakdown →

17.

Liu, Gang, Haiying Chen, Hua Liu, Wenbo Zhang, & Jia Zhou. (2020). Emerging roles of SIRT6 in human diseases and its modulators. Medicinal Research Reviews. 41(2). 1089–1137. 130 indexed citations

18.

Lin, Yuqi, Rong Liu, Ping Zhao, et al.. (2018). Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer. European Journal of Medicinal Chemistry. 146. 354–367. 14 indexed citations

19.

Zhou, Jia, et al.. (2016). Research Progress of the Mechanism of Combined Acupuncture-medication Anesthesia in Protecting Internal Organs During Perioperative Period of Pneumonectomy. 35(8). 901.

20.

Wu, Jing, Ye Ding, Zhongmei Zhou, et al.. (2016). A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Letters. 380(2). 393–402. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact